VIVS
VivoSim Labs, INC.
Key Financials
Revenue
$144000
↑ 32.1%
Net Income
$-2488000
↑ 83.0%
Total Assets
$14.7M
↑ 130.7%
EPS (Diluted)
$-1.70
↓ 6.2%
Total Liabilities
$4.2M
↑ 51.3%
Shareholders' Equity
$10.5M
↑ 2782.4%
Cash & Equivalents
$11.3M
↑ 289.9%
Operating Cash Flow
$-9461000.00
↑ 35.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 4/6/2026 | View on SEC |
| 8-K | 4/3/2026 | View on SEC |
| 424B4 | 4/2/2026 | View on SEC |
| EFFECT | 3/31/2026 | View on SEC |
| S-1/A | 3/31/2026 | View on SEC |
| S-1 | 3/27/2026 | View on SEC |
| DRS | 3/9/2026 | View on SEC |
| 10-Q | 2/11/2026 | View on SEC |
| 4 | 1/29/2026 | View on SEC |
| 4 | 1/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VIVS |
| Company Name | VivoSim Labs, INC. |
| CIK | 1497253 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | 858-224-1000 |